TACR1 and melanoma: Among NK-1R antitumor drugs, the inhibitor aprepitant should be highlighted, having shown traslational potential in a broad spectrum of cancers, such as breast, colon, gastric, laryngeal, lung and pancreatic cancers, esophageal squamous cell carcinoma, leukemias, retinoblastoma, neuroblastoma, glioma, osteosarcoma or melanoma [25].